Health Condition 1: N970- Female infertility associated withanovulation Health Condition 2: N979- Female infertility, unspecified
Conditions
Interventions
Intervention1: In Group A, patients will receive a maintenance dose of 0.7 mcg/kg/hr dexmedetomidine, titrated to maintain sedation: In Group A, patients will receive an induction dose of 1 mcg/kg dex
Sponsors
Aditi Singh
Eligibility
Inclusion criteria
Inclusion criteria: Women undergoing elective oocyte retrieval. ASA I & II patients. Age between 18 years to 40 years. Patients willing to provide informed consent.
Exclusion criteria
Exclusion criteria: Patients who deny consent will not be included in the study. ASA III and ASA IV. Past history of allergy to dexmedetomidine and ketamine. Chronic sedative and opioid use
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the post operative recovery time measured from procedure end to Modified Aldrete score more than equal to 9 at 10mis, 20 mins and 30 minsTimepoint: To compare the post operative recovery time measured from procedure end to Modified Aldrete score more than equal to 9 at 10 mins,20 mins and 30 mins | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate & compare hemodynamic stability in terms of heart rate & blood pressure at various time intervals intraoperatively. To assess pain score (VAS Score) on complete recovery, at thirty minutes & at sixty minutes from the end of the procedure. To evaluate the need for rescue analgesia. To investigate the adverse effects like nausea, vomiting, dizziness, hallucinations during recovery time. Timepoint: complete recovery, at 30 minutes & at 60 minutes from the end of the procedure | — |
Countries
India
Contacts
Public ContactJimna Joy
Armed Forces Medical College, Pune
Outcome results
None listed